Iopamidol

Identification

Name
Iopamidol
Accession Number
DB08947
Type
Small Molecule
Groups
Approved
Description

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Structure
Thumb
Synonyms
Not Available
External IDs
B 15 000 / SQ 13,396 / SQ 13396 / SQ-13396
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iopamidol Injection USPSolution76 %IntravascularHospira, Inc.Not applicableNot applicableCanada
Iopamidol Injection USPSolution61 %IntravascularHospira, Inc.Not applicableNot applicableCanada
IsovueSolution612 mg/1mLIntravascularApothecary Shop Wholesale Inc.2011-07-012011-08-31Us
Isovue 128 Inj 26%Liquid26 %IntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1988-12-311998-07-30Canada
Isovue 128 InjectionLiquid26 %IntravenousBracco Imaging S.P.A.1998-01-082000-07-20Canada
Isovue 200Injection, solution408 mg/1mLIntravascularBIPSO GmbH1985-12-31Not applicableUs
Isovue 200Injection, solution408 mg/1mLIntravascularBracco Diagnostics, Inc1985-12-31Not applicableUs
Isovue 200 Inj 41%Liquid41 %IntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1985-12-311998-07-30Canada
Isovue 200 InjectionLiquid41 %IntravenousBracco Imaging S.P.A.1998-01-08Not applicableCanada
Isovue 250Injection, solution510 mg/1mLIntravascularBIPSO GmbH1985-12-31Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-iopamidolLiquid200 mgIntravenous; SubarachnoidPharmascience IncNot applicableNot applicableCanada
PMS-iopamidolLiquid370 mgIntravenousPharmascience IncNot applicableNot applicableCanada
PMS-iopamidolLiquid300 mgIntravenousPharmascience IncNot applicableNot applicableCanada
International/Other Brands
Gastromiro (Bracco) / Iopamiro (Bracco) / Iopamiron (Bayer) / Isovue (Bracco) / Jopamiro (Bracco) / Moiopamin (Hikari Seiyaku) / Oypalomin (Fuji Yakuhin) / Solutrast (Bracco)
Categories
UNII
JR13W81H44
CAS number
60166-93-0
Weight
Average: 777.0853
Monoisotopic: 776.854094955
Chemical Formula
C17H22I3N3O8
InChI Key
XQZXYNRDCRIARQ-LURJTMIESA-N
InChI
InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
IUPAC Name
N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-1,2-dihydroxypropylidene]amino}-2,4,6-triiodobenzene-1,3-dicarboximidic acid
SMILES
[H][C@@](C)(O)C(O)=NC1=C(I)C(C(O)=NC(CO)CO)=C(I)C(C(O)=NC(CO)CO)=C1I

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AldesleukinThe risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.
MetforminThe risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.
Food Interactions
Not Available

References

General References
  1. Tian FX, Xu B, Lin YL, Hu CY, Zhang TY, Gao NY: Photodegradation kinetics of iopamidol by UV irradiation and enhanced formation of iodinated disinfection by-products in sequential oxidation processes. Water Res. 2014 Jul 1;58:198-208. doi: 10.1016/j.watres.2014.03.069. Epub 2014 Apr 5. [PubMed:24762552]
External Links
KEGG Drug
D01797
PubChem Compound
65492
PubChem Substance
310264913
ChemSpider
58940
ChEBI
31711
ChEMBL
CHEMBL1200932
Drugs.com
Drugs.com Drug Page
Wikipedia
Iopamidol
ATC Codes
V08AB04 — Iopamidol
AHFS Codes
  • 36:68.00 — Roentgenography
FDA label
Download (715 KB)
MSDS
Download (133 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingOtherMetastatic Castration-Resistant Prostate Cancer (mCRPC)1
1, 2CompletedDiagnosticHealthy Volunteers1
2CompletedDiagnosticCoronary Artery Disease1
3CompletedDiagnosticCoronary Computed Tomographic Angiography1
4CompletedNot AvailableDrug Safety1
4CompletedNot AvailableIV Contrast Dosing1
4CompletedNot AvailablePatient Comfort and Safety1
4CompletedNot AvailableThoracic Aortic Aneurysm (TAA)1
4CompletedDiagnosticCoronary Artery Stenosis2
4CompletedDiagnosticPeripheral Obliterative Arteriopathy2
4CompletedDiagnosticPulmonary Embolism (PE)1
4CompletedTreatmentGastrointestinal Complications1
4Not Yet RecruitingDiagnosticPercutaneous Coronary Intervention1
4RecruitingSupportive CareContrast Agent With Lean Body Weight / Dosing Contrast Agent Using Lean Body Weight1
4TerminatedDiagnosticChronic Renal Diseases1
4TerminatedDiagnosticCoronary Artery Stenosis1
4TerminatedDiagnosticDiabetes Mellitus (DM) / Impaired Renal Function1
4TerminatedDiagnosticDiabetes Mellitus (DM) / Renal Insufficiency,Chronic1
Not AvailableEnrolling by InvitationDiagnosticCT of the Abdomen and Pelvis With Contrast Material1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravascular61 %
SolutionIntravascular76 %
SolutionIntravascular612 mg/1mL
LiquidIntravenous26 %
Injection, solutionIntravascular408 mg/1mL
LiquidIntravenous41 %
Injection, solutionIntravascular510 mg/1mL
Injection, solutionIntravascular612 mg/1mL
Injection, solutionIntravenous612 mg/1mL
LiquidIntravenous61 %
LiquidIntravascular61 %
Injection, solutionIntravascular755 mg/1mL
Injection, solutionIntravenous755 mg/1mL
LiquidIntravenous76 %
LiquidIntravascular76 %
Injection, solutionIntrathecal408 mg/1mL
Injection, solutionIntrathecal612 mg/1mL
SolutionIntrathecal408 mg/1mL
SolutionIntrathecal612 mg/1mL
LiquidIntravenous300 mg
LiquidIntravenous370 mg
LiquidIntravenous; Subarachnoid200 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.117 mg/mLALOGPS
logP-0.97ALOGPS
logP1.62ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.15ChemAxon
pKa (Strongest Basic)1.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area198.92 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity141.46 m3·mol-1ChemAxon
Polarizability55.67 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Iodobenzenes
Alternative Parents
Aryl iodides / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organoiodides / Hydrocarbon derivatives
Substituents
Iodobenzene / Aryl halide / Aryl iodide / Secondary alcohol / Carboximidic acid / Carboximidic acid derivative / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organoiodine compound, benzenedicarboxamide, pentol (CHEBI:31711)

Drug created on May 27, 2014 10:50 / Updated on September 18, 2018 23:02